<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00118313</url>
  </required_header>
  <id_info>
    <org_study_id>11490</org_study_id>
    <secondary_id>UVACC-MEL-45</secondary_id>
    <secondary_id>UVACC-34204</secondary_id>
    <nct_id>NCT00118313</nct_id>
  </id_info>
  <brief_title>Vaccine Therapy With or Without Imiquimod in Treating Patients Who Have Undergone Surgery for Stage II, Stage III, or Stage IV Melanoma</brief_title>
  <official_title>Evaluation of Different Adjuvants for the Transdermal Administration of a Peptide-Based Vaccine in Participants With High-Risk Melanoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Craig L Slingluff, Jr</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Virginia</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Vaccines made from peptides may help the body build an effective immune response&#xD;
      to kill tumor cells. Biological therapies, such as imiquimod, may stimulate the immune system&#xD;
      in different ways and stop tumor cells from growing. Giving vaccine therapy together with&#xD;
      imiquimod after surgery may help the body kill any remaining tumor cells.&#xD;
&#xD;
      PURPOSE: This randomized phase I trial is studying the side effects and best way to give&#xD;
      vaccine therapy with or without imiquimod in treating patients who have undergone surgery for&#xD;
      stage II, stage III, or stage IV melanoma.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  Determine the safety of adjuvant transdermal vaccine therapy comprising multi-epitope&#xD;
           melanoma peptides (MP), tetanus toxoid helper peptide (TET), and sargramostim (GM-CSF)&#xD;
           in combination with Montanide ISA-51 or dimethyl sulfoxide with or without imiquimod in&#xD;
           patients who have undergone surgical resection for stage II-IV melanoma.&#xD;
&#xD;
        -  Determine, preliminarily, the immunogenicity of these regimens in these patients.&#xD;
&#xD;
        -  Correlate, preliminarily, transdermal administration of these vaccines with the&#xD;
           recruitment and maturation of epidermal Langerhans cells in these patients.&#xD;
&#xD;
        -  Determine, preliminarily, the effects of timing of subsequent vaccine therapy comprising&#xD;
           MP, TET, and GM-CSF emulsified in Montanide ISA-51, administered intradermally and&#xD;
           subcutaneously, on the persistence of immune response in these patients.&#xD;
&#xD;
      OUTLINE: This is a randomized, open-label study. Patients are randomized to 1 of 4 treatment&#xD;
      arms.&#xD;
&#xD;
        -  Arm I: Patients receive vaccine therapy comprising multi-epitope melanoma peptides (MP),&#xD;
           tetanus toxoid helper peptide (TET), and sargramostim (GM-CSF) emulsified in Montanide&#xD;
           ISA-51 transdermally (TD) on days 1, 8, and 15. Patients then receive the vaccine&#xD;
           intradermally (ID) and subcutaneously (SC) on days 29, 50, 71, 92, 113, and 134.&#xD;
&#xD;
        -  Arm II: Patients receive vaccine therapy as in arm I. Patients also receive imiquimod&#xD;
           topically on days 0, 7, and 14.&#xD;
&#xD;
        -  Arm III: Patients receive vaccine therapy comprising MP, TET, GM-CSF, and dimethyl&#xD;
           sulfoxide TD on days 1, 8, and 15. Patients then receive vaccine therapy comprising MP,&#xD;
           TET, and GM-CSF emulsified in Montanide ISA-51 ID and SC on days 29, 50, 71, 92, 113,&#xD;
           and 134.&#xD;
&#xD;
        -  Arm IV: Patients receive vaccine therapy as in arm III and imiquimod as in arm II.&#xD;
&#xD;
      In all arms, treatment continues in the absence of disease progression or unacceptable&#xD;
      toxicity.&#xD;
&#xD;
      After completion of study treatment, patients are followed at 3 and 5 weeks and then at&#xD;
      disease progression.&#xD;
&#xD;
      PROJECTED ACCRUAL: A maximum of 26 patients (approximately 6 per treatment arm) will be&#xD;
      accrued for this study within approximately 2 years.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 4, 2004</start_date>
  <completion_date type="Actual">July 28, 2006</completion_date>
  <primary_completion_date type="Actual">July 28, 2006</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety if less than 33% of patients experience a dose-limiting at day 22</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Immune response by Elispot assay at day 22</measure>
  </secondary_outcome>
  <condition>Melanoma (Skin)</condition>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>incomplete Freund's adjuvant</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>multi-epitope melanoma peptide vaccine</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>sargramostim</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>tetanus toxoid helper peptide</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>dimethyl sulfoxide</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>imiquimod</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>adjuvant therapy</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically or cytologically confirmed melanoma&#xD;
&#xD;
               -  Stage II-IV disease&#xD;
&#xD;
          -  Has undergone surgical resection within the past 12 months&#xD;
&#xD;
               -  No clinical or radiological evidence of disease after surgical resection&#xD;
&#xD;
               -  Must have ≥ 1 undissected axillary and/or inguinal lymph node basin&#xD;
&#xD;
          -  HLA-A1, -A2, or -A3 positive&#xD;
&#xD;
          -  Ineligible for OR refused interferon&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age&#xD;
&#xD;
          -  12 and over&#xD;
&#xD;
        Performance status&#xD;
&#xD;
          -  ECOG 0-1&#xD;
&#xD;
        Life expectancy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Hematopoietic&#xD;
&#xD;
          -  Absolute neutrophil count &gt; 1,000/mm^3&#xD;
&#xD;
          -  Platelet count &gt; 100,000/mm^3&#xD;
&#xD;
          -  Hemoglobin &gt; 9 g/dL&#xD;
&#xD;
        Hepatic&#xD;
&#xD;
          -  AST and ALT ≤ 2.5 times upper limit of normal (ULN)&#xD;
&#xD;
          -  Bilirubin ≤ 2.5 times ULN&#xD;
&#xD;
          -  Lactic dehydrogenase ≤ 1.5 times ULN&#xD;
&#xD;
          -  Alkaline phosphatase ≤ 2.5 times ULN&#xD;
&#xD;
          -  Hepatitis C negative&#xD;
&#xD;
        Renal&#xD;
&#xD;
          -  Creatinine ≤ 1.5 times ULN&#xD;
&#xD;
        Cardiovascular&#xD;
&#xD;
          -  No New York Heart Association class III or IV heart disease&#xD;
&#xD;
        Immunologic&#xD;
&#xD;
          -  HIV negative&#xD;
&#xD;
          -  No known or suspected allergy to any component of the study vaccines&#xD;
&#xD;
          -  No autoimmune disorder with visceral involvement&#xD;
&#xD;
          -  No prior active autoimmune disorder requiring cytotoxic or immunosuppressive therapy&#xD;
&#xD;
          -  The following immunologic conditions are allowed:&#xD;
&#xD;
               -  Laboratory evidence of autoimmune disease (e.g., positive anti-nuclear antibody&#xD;
                  titer) without symptoms&#xD;
&#xD;
               -  Clinical evidence of vitiligo&#xD;
&#xD;
               -  Other forms of depigmenting illness&#xD;
&#xD;
               -  Mild arthritis requiring non-steroidal anti-inflammatory drugs&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception&#xD;
&#xD;
          -  Weight ≥ 110 lbs&#xD;
&#xD;
          -  No uncontrolled diabetes&#xD;
&#xD;
               -  Hemoglobin A1C &lt; 7% (for patients with diabetes)&#xD;
&#xD;
          -  No medical contraindication or potential problem that would preclude study compliance&#xD;
&#xD;
          -  No known active addiction to alcohol or drugs&#xD;
&#xD;
          -  No recent (within the past year) or ongoing illicit IV drug use&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy&#xD;
&#xD;
          -  Prior vaccinations that resulted in recurrent disease during or after vaccine&#xD;
             administration allowed provided the last vaccination was administered more than 12&#xD;
             weeks ago&#xD;
&#xD;
          -  Prior multi-epitope melanoma peptide vaccine that resulted in a negative immune&#xD;
             response allowed&#xD;
&#xD;
          -  More than 4 weeks since prior and no concurrent interferon (e.g., Intron-A®),&#xD;
             interleukins (e.g., Proleukin®), or growth factors (e.g., Procrit®, Aranesp®, or&#xD;
             Neulasta®)&#xD;
&#xD;
          -  More than 4 weeks since prior and no concurrent allergy desensitization injections&#xD;
&#xD;
          -  No influenza vaccine for at least 2 weeks before or after study vaccine administration&#xD;
&#xD;
        Chemotherapy&#xD;
&#xD;
          -  More than 4 weeks since prior chemotherapy (6 weeks for nitrosoureas [e.g., carmustine&#xD;
             or lomustine])&#xD;
&#xD;
          -  No concurrent chemotherapy, including nitrosoureas&#xD;
&#xD;
        Endocrine therapy&#xD;
&#xD;
          -  More than 4 weeks since prior and no concurrent oral or parenteral corticosteroids&#xD;
             (e.g., prednisone)&#xD;
&#xD;
          -  No prior or concurrent inhaled steroids (e.g., Advair®, Flovent®, Azmacort®)&#xD;
&#xD;
          -  Concurrent topical corticosteroids allowed&#xD;
&#xD;
        Radiotherapy&#xD;
&#xD;
          -  More than 4 weeks since prior and no concurrent radiotherapy&#xD;
&#xD;
          -  Prior stereotactic radiosurgery allowed provided it was completed within the past 12&#xD;
             months&#xD;
&#xD;
        Surgery&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  More than 4 weeks since prior surgical resection of metastatic lesion(s)&#xD;
&#xD;
          -  No concurrent surgery requiring general anesthesia&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  More than 4 weeks since prior and no other concurrent investigational agents&#xD;
&#xD;
          -  More than 30 days since prior and no concurrent participation in another clinical&#xD;
             study&#xD;
&#xD;
          -  No other concurrent immunosuppressive therapy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>120 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Craig L. Slingluff, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Virginia</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Virginia Cancer Center</name>
      <address>
        <city>Charlottesville</city>
        <state>Virginia</state>
        <zip>22908</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>July 8, 2005</study_first_submitted>
  <study_first_submitted_qc>July 8, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 11, 2005</study_first_posted>
  <last_update_submitted>March 26, 2020</last_update_submitted>
  <last_update_submitted_qc>March 26, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 27, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University of Virginia</investigator_affiliation>
    <investigator_full_name>Craig L Slingluff, Jr</investigator_full_name>
    <investigator_title>Professor, Department of Surgery</investigator_title>
  </responsible_party>
  <keyword>stage II melanoma</keyword>
  <keyword>stage III melanoma</keyword>
  <keyword>stage IV melanoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Melanoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Imiquimod</mesh_term>
    <mesh_term>Sargramostim</mesh_term>
    <mesh_term>Freund's Adjuvant</mesh_term>
    <mesh_term>Dimethyl Sulfoxide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

